AIM-HI Accelerator Fund Too many scientific breakthroughs are left on the laboratory bench instead of being translated into next-generation cancer treatments. This is largely due to the lack of seed funding for early-stage oncology startups, the so-called “Valley of Death” during which investment is too risky for traditional VCs and pharmaceutical